(Albany, US) DelveInsight launched a new report on “Peanut Allergy Market Insights, Epidemiology and Market Forecast-2030”.
DelveInsight’s “Peanut Allergy – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Peanut Allergy, historical and forecasted epidemiology as well as the Peanut Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts of the report
1. As per DelveInsight estimates, total prevalent population of Peanut Allergy in the 7MM was found to be 8,640,527 in 2017.
2. As per DelveInsight analysis, it is observed that, Japan has the least number of prevalent cases (1,548,318 for 2017) of Peanut Allergy, among the 7MM.
3. The total cases of mild and moderate to severe Peanut Allergy in the US varied as 2,341,384 and 1,153,219 respectively.
Key benefits of the report
1. Peanut Allergy market report covers a descriptive overview and comprehensive insight of the Peanut Allergy epidemiology and Peanut Allergy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Peanut Allergy market report provides insights on the current and emerging therapies.
3. Peanut Allergy market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Peanut Allergy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Peanut Allergy market.
Request for sample pages : https://www.delveinsight.com/sample-request/peanut-allergy-market
“According to DelveInsight, most of the patients diagnosed with Peanut Allergy were male.”
Food allergy is an abnormal response to a food triggered by the body’s immune system. There are several types of immune response to food. A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely.
Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction- even trace levels of peanut are capable of causing a hypersensitive reaction.
The symptoms of peanut allergy vary from mild to severe, from swollen lips, shortness of breath to ananaphylactic shock, which is potentially fatal.
– Mild to moderate symptoms are: Itchy skin or hives, which can appear as small spots or largewelts, an itching or tingling sensation in or around the mouth or throat, nausea, a runny or congested nose.
– The most severe allergic reaction to peanuts is anaphylaxis, a life-threatening whole-body response to an allergen. Symptoms include impaired breathing, swelling in the throat, a sudden drop in blood pressure, pale skin or blue lips, fainting and dizziness.
“According to DelveInsight, Among the EU5 countries, France had the highest prevalent population of Peanut Allergy with 614,959 cases, followed by Germany and the United Kingdom. “
The launch of the emerging therapies is expected to significantly impact Peanut Allergy treatment scenario in the upcoming years:-
Drugs covered
- Palforzia
- Viaskin Peanut
- ANB020
- Omalizumab
And many others
The key players in Peanut Allergy market are:
- Aimmune Therapeutics
- DBV Technologies
- AnaptysBio
- Genentech
And many others
Request for sample pages : https://www.delveinsight.com/sample-request/peanut-allergy-market
Table of contents
1. Key Insights
2. Peanut Allergy: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Peanut Allergy in 2017
2.2. Total Market Share (%) Distribution of Peanut Allergy in 2030
3. Peanut Allergy: Disease Background and Overview
3.1.1.Introduction
3.1.2.Peanut Allergen
3.1.3.Characterization of Peanut Allergens
3.2. Clinical Presentation
3.2.1.Clinical Symptoms
3.3. Causes and Risk Factors
3.3.1.Risk Factors
3.4. Pathophysiology of Peanut Allergy
3.5. Cross-reactivity with Other Foods
3.5.1.Outgrowing Peanut Allergy
3.6. Diagnosis of Peanut Allergy
3.6.1.History, the key Diagnostic Test
3.6.2.Skin Prick Tests (SPT)
3.6.3.Serum Peanut-IgE Concentration
3.6.4.Component Testing
3.6.5.Peanut-Induced Anaphylactic Reactions
4. Epidemiology and Patient Population
4.1. Key Findings
5. Total Prevalent Population of Peanut Allergy in 7MM
6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Prevalent Population of Peanut Allergy in the United States (2017–2030)
6.3. Gender-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)
6.4. Age-Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)
6.5. Severity–Specific Prevalent Population of Peanut Allergy in the United States (2017–2030)
7. EU5 Epidemiology
7.1. Germany Epidemiology
7.1.1.Assumptions and Rationale
7.1.2.Total Prevalent Population of Peanut Allergy in Germany (2017–2030)
7.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)
7.1.4.Age-Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)
7.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Germany (2017–2030)
7.2. France Epidemiology
7.2.1.Assumptions and rationale
7.2.2.Total Prevalent Population of Peanut Allergy in France (2017–2030)
7.2.3.Gender-Specific Prevalent Population of Peanut Allergy in France (2017–2030)
7.2.4.Age-Specific Prevalent Population of Peanut Allergy in France (2017–2030)
7.2.5.Severity–Specific Prevalent Population of Peanut Allergy in France (2017–2030)
7.3. Italy Epidemiology
7.3.1.Assumptions and Rationale
7.3.2.Total Prevalent Population of Peanut Allergy in Italy (2017–2030)
7.3.3.Gender-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)
7.3.4.Age-Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)
7.3.5.Severity–Specific Prevalent Population of Peanut Allergy in Italy (2017–2030)
7.4. Spain Epidemiology
7.4.1.Assumptions and Rationale
7.4.2.Total Prevalent Population of Peanut Allergy in Spain (2017–2030)
7.4.3.Gender-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)
7.4.4.Age-Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)
7.4.5.Severity–Specific Prevalent Population of Peanut Allergy in Spain (2017–2030)
7.5. United Kingdom Epidemiology
7.5.1.Assumptions and Rationale
7.5.2.Total Prevalent Population of Peanut Allergy in the UK (2017–2030)
7.5.3.Gender-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)
7.5.4.Age-Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)
7.5.5.Severity–Specific Prevalent Population of Peanut Allergy in the UK (2017–2030)
8. Japan Epidemiology
8.1.1.Assumptions and Rationale
8.1.2.Total Prevalent Population of Peanut Allergy in Japan (2017–2030)
8.1.3.Gender-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)
8.1.4.Age-Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)
8.1.5.Severity–Specific Prevalent Population of Peanut Allergy in Japan (2017–2030)
9. Treatment Algorithm, Current Treatment, and Medical Practices
9.1. Primary Prevention
9.2. Management
9.3. Oral Immunotherapy
9.4. Treatment Guidelines
9.4.1.Practice Guidelines for Peanut Allergies
10. Unmet Needs
11. Marketed Therapies
11.1. Palforzia: Aimmune Therapeutics
11.1.1.Product Description
11.1.2.Mechanism of Action
11.1.3.Regulatory Milestones
11.1.4.Safety and Efficacy
11.1.5.Clinical Trial Information
11.1.6.Advantages and Disadvantages
11.1.7.Product Profile
12. Emerging Therapies
12.1. Key Cross Competition
12.2. Viaskin Peanut: DBV Technologies
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. ANB020: AnaptysBio
12.3.1. Drug Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Omalizumab: Genentech
12.4.1. Drug Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
Drug list continued..
13. Peanut Allergy: 7MM Market Analysis
13.1. Key Findings
13.2. Market Size of Peanut Allergy in 7MM (2017–2030)
14. United States: Market Outlook
14.1. United States Market Size
14.1.1. The total market size of Peanut Allergy
14.1.2. Market Size of Peanut Allergy by Therapies in the US
15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. The total market size of Peanut Allergy
15.1.2. Market Size of Peanut Allergy by therapies in Germany
15.2. France Market Size
15.2.1. The total market size of Peanut Allergy
15.2.2. Market Size of Peanut Allergy by therapies in France
15.3. Italy Market Size
15.3.1. The total market size of Peanut Allergy
15.3.2. Market Size of Peanut Allergy by therapies in Italy
15.4. Spain Market Size
15.4.1. The total market size of Peanut Allergy
15.4.2. Market Size of Peanut Allergy by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. The total market size of Peanut Allergy
15.5.2. Market Size of Peanut Allergy by therapies in the UK
16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. The total market size of Peanut Allergy
16.1.2. Market Size of Peanut Allergy by therapies in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Related Reports:
Peanut Allergy – Pipeline Insights, 2020
The Peanut Allergy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peanut Allergy across the complete product development cycle, including all clinical and nonclinical stages.
Peanut Allergy – Epidemiology Forecast to 2030
The Peanut Allergy epidemiology covered in the report provides historical as well as forecasted Peanut Allergy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/